摘要
目的 :探讨益气活血药通脉口服液 (由黄芪、三七组成 )对大鼠慢性肾炎“气虚血瘀证”模型的治疗机理。方法 :在大鼠慢性肾炎模型的基础上 ,加建大鼠“气虚血瘀证”模型 ,随机分通脉口服液高剂量治疗组、通脉口服液低剂量治疗组、金水宝治疗组、模型对照组及正常对照组 ,治疗 4周后 ,进行组间疗效比较。结果 :通脉口服液组对模型大鼠的一般状态、生化指标 (包括T淋巴细胞亚群和血液流变学等 )及肾组织病理的损害均有明显的改善作用 ,且高剂量组疗效要优于金水宝组和低剂量组。结论 :通脉口服液通过益气活血 ,调节了模型大鼠的免疫功能 ,改善了血液高凝状态 ,减轻了肾脏病理损害 ,从而达到改善和稳定肾功能的目的 。
The mechanism of Tongmai Oral Liquid (TOL) for chronic nephritis rat model with Qi-deficiency and blood-stasis syndrome was studied.The model was established by adding Qi-deficiency and blood-stasis syndrome to the chronic nephritis rats. The experimental rats were randomly allocated to 5 groups: Group A (treated with high dosage of TOL), Group B (treated with low dosage of TOL), Group C (treated with Jinshuibao), Group D (model control group) and Group E (normal control group). After 4 weeks of treatment, general health state, biochemical indexes including T lymphocyte subgroup and blood rheology, and pathological damage of kidney tissue were much improved in Group A than Group B and Group C. It is indicated that TOL can improve the renal function and delay the occurrence of glomerular arteriosclerosis in rats by reinforcing Qi, activating blood flow, regulating immune function, lessening the hypercoagulative state and reducing renal damage.
出处
《广州中医药大学学报》
CAS
2000年第4期332-336,共5页
Journal of Guangzhou University of Traditional Chinese Medicine
基金
广东省重点科技攻关项目!(编号 :970 5 3)
关键词
慢性肾炎
血瘀证
中医药疗法
通脉口服液
TONGMAI ORAL LIQUID/pharmacology
ASTRAGALUS MEMBRANACEUS/ther. use
PANAX PSEUDOGINSENG/ther. use
NEPHRITIS/ TCD therapy
T-LYMPHOCYTES/immunology
BLOOD RHEOLOGY/drug effects
DISEASE MODELS, ANIMAL
RATS
